Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

BACKGROUND: Activation of melanocortin 1 receptor (MC1R) is known to exert broad anti-inflammatory and anti-fibrotic effects. The purpose of this study is to investigate the potential of dersimelagon, a novel oral MC1R agonist, as a therapeutic agent for systemic sclerosis (SSc). METHODS: The effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Masahiro, Suzuki, Tsuyoshi, Kawano, Yuko, Kojima, Shinji, Miyashiro, Masahiko, Matsumoto, Atsuhiro, Kania, Gabriela, Błyszczuk, Przemysław, Ross, Rebecca L., Mulipa, Panji, Del Galdo, Francesco, Zhang, Yun, Distler, Jörg H. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434962/
https://www.ncbi.nlm.nih.gov/pubmed/36050717
http://dx.doi.org/10.1186/s13075-022-02899-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434962/
https://www.ncbi.nlm.nih.gov/pubmed/36050717
http://dx.doi.org/10.1186/s13075-022-02899-3

Ejemplares similares